Silencing RPL8 inhibits the progression of hepatocellular carcinoma by down-regulating the mTORC1 signalling pathway

被引:6
|
作者
Sun, Tao [1 ]
Zhu, Weiying [2 ]
Ru, Qingjing [1 ]
Zheng, Yi [1 ]
机构
[1] Zhejiang Chinese Med Univ, Dept Infect Dis, Affiliated Hosp 2, 318 Chaowang Rd, Hangzhou 310005, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou 310053, Zhejiang, Peoples R China
关键词
LIHC; RPL8; mTORC1 signalling pathway; Migration; EXPRESSION; ASSOCIATION; LNCRNA;
D O I
10.1007/s13577-022-00852-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
This study aimed to explore the role of ribosomal protein L8 (RPL8) in controlling hepatocellular carcinoma (LIHC) development. We measured RPL8 expression, apoptosis, cell viability, proliferation, migration, invasion, glucose uptake, lactate production, and the ATP/ADP ratio of LIHC cells to investigate the effect of RPL8 on LIHC. Bioinformatic analysis was employed to analyse RPL8 expression and its potential mechanism in LIHC. RPL8 was upregulated in LIHC tissues and cells. RPL8 silencing accelerated apoptosis and suppressed viability, growth, and movement of LIHC cells. Additionally, RPL8 silencing inhibited glycolysis in LIHC cells. Bioinformatic analysis revealed that RPL8 is regulated by the upstream transcription factor upstream stimulating factor 1 (USF1) and activates the mTORC1 signalling pathway. USF1 overexpression eliminated the inhibitory effect of RPL8 silencing in LIHC cells. RPL8 overexpression increased cell growth, movement, and glycolysis in LIHC. However, inhibition of the mTORC1 signalling pathway eliminated the effect of RPL8 overexpression on LIHC cells. In conclusion, RPL8 may affect LIHC progression by regulating the mTORC1 signalling pathway.
引用
收藏
页码:725 / 737
页数:13
相关论文
共 50 条
  • [31] Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway
    Hong, Han
    Jin, Zhengkang
    Qian, Tao
    Xu, Xiaoyong
    Zhu, Xiang
    Fei, Qiang
    Yang, Jiamei
    Sui, Chengjun
    Xu, Minhui
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [32] The MicroRNA miR-139 Suppresses Metastasis and Progression of Hepatocellular Carcinoma by Down-regulating Rho-Kinase 2
    Wong, Carmen Chak-Lui
    Wong, Chun-Ming
    Tung, Edmund Kwok-Kwun
    Au, Sandy Leung-Kuen
    Lee, Joyce Man-Fong
    Poon, Ronnie Tung-Ping
    Man, Kwan
    Ng, Irene Oi-Lin
    GASTROENTEROLOGY, 2011, 140 (01) : 322 - 331
  • [33] DACH1 inhibits nuclear localization of β-catenin via down-regulating EGFR/ERK/FoxM1 axis in hepatocellular carcinoma cells
    Zhu, Hongbin
    Zhu, Hongbin
    Wang, Dongxu
    He, Yuzhuo
    Ma, Longteng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 18 - 18
  • [34] WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
    Long Lv
    Gong Chen
    Jianping Zhou
    Jun Li
    Jianping Gong
    Journal of Experimental & Clinical Cancer Research, 34
  • [35] WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
    Lv, Long
    Chen, Gong
    Zhou, Jianping
    Li, Jun
    Gong, Jianping
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
  • [36] DACH1 inhibits nuclear localization of β-catenin via down-regulating EGFR/ERK/FoxM1 axis in hepatocellular carcinoma cells
    Zhu, Hongbin
    Zhu, Hongbin
    Wang, Dongxu
    He, Yuzhuo
    Ma, Longteng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 18 - 18
  • [37] Loss of α1,6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways
    Wang, Yuqin
    Fukuda, Tomohiko
    Isaji, Tomoya
    Lu, Jishun
    Im, Sanghun
    Hang, Qinglei
    Gu, Wei
    Hou, Sicong
    Ohtsubo, Kazuaki
    Gu, Jianguo
    FASEB JOURNAL, 2015, 29 (08): : 3217 - 3227
  • [38] Combined Targeting of mTORC1 and mTORC2 Synergistically Inhibits Proliferation of Hepatocellular Carcinoma Cells: Effects of Everolimus and Ku0063794
    Kim, Say-June
    Choi, Ho-Joong
    Kim, Dong-Goo
    LIVER TRANSPLANTATION, 2014, 20 : S235 - S235
  • [39] Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway
    Ding, Wenbo
    Chen, Xiuwei
    Yang, Licheng
    Chen, Yaping
    Song, Jie
    Bu, Weiquan
    Feng, Bin
    Zhang, Meng
    Luo, Yi
    Jia, Xiaobin
    Feng, Liang
    INTEGRATIVE CANCER THERAPIES, 2022, 21
  • [40] Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway
    Ding, Wenbo
    Chen, Xiuwei
    Yang, Licheng
    Chen, Yaping
    Song, Jie
    Bu, Weiquan
    Feng, Bin
    Zhang, Meng
    Luo, Yi
    Jia, Xiaobin
    Feng, Liang
    INTEGRATIVE CANCER THERAPIES, 2022, 21